Bulletin
Investor Alert

London Markets Open in:

Regulus Therapeutics Inc.

NAS: RGLS

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Nov 25, 2022, 1:00 p.m.

/zigman2/quotes/202916513/composite

$

1.76

Change

+0.08 +4.46%

Volume

Volume 1

Quotes are delayed by 20 min

/zigman2/quotes/202916513/composite

Previous close

$ 1.72

$ 1.68

Change

-0.04 -2.04%

Day low

Day high

$1.61

$1.80

Open

52 week low

52 week high

$1.33

$4.19

Open

Company Description

Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial ...

Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded on September 5, 2007 and is headquartered in San Diego, CA.

Valuation

Price to Book Ratio

0.84

Enterprise Value to EBITDA

0.87

Efficiency

Liquidity

Current Ratio

11.90

Quick Ratio

11.90

Cash Ratio

11.56

Profitability

Return on Assets

-52.44

Return on Equity

-68.68

Return on Total Capital

-59.32

Capital Structure

Total Debt to Total Assets

11.22

Officers and Executives

Name Age Officer Since Title
Mr. Joseph P. Hagan 52 2016 President, CEO, CFO & Director
Ms. Crispina Calsada 51 2019 Chief Financial Officer
Dr. Denis Drygin 48 2020 Chief Scientific Officer
Dr. Amin Kamel - 2022 Vice President-DMPK
Mr. Daniel Penksa 35 2015 Controller

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
03/01/2022 Denis Drygin
Chief Scientific Officer
76,686   Acquisition at $0.23 per share. 17,637
02/04/2022 Denis Drygin
Chief Scientific Officer
23,314   Acquisition at $0.23 per share. 5,362
01/26/2022 Joseph P. Hagan
President and CEO; Director
100,000   Acquisition at $0.22 per share. 22,000
11/30/2021 Stelios Papadopoulos
Director
2,222,222   Award at $0.36 per share. 799,999
05/17/2021 Joseph P. Hagan
President and CEO; Director
4,186   Disposition at $0.89 per share. 3,725
05/17/2021 Christopher Aker
Sr. VP & General Counsel
860   Disposition at $0.89 per share. 765
04/14/2021 Joseph P. Hagan
President and CEO; Director
75,850   Derivative/Non-derivative trans. at $0 per share. 0
02/16/2021 Joseph P. Hagan
President and CEO; Director
4,144   Disposition at $1.72 per share. 7,127
02/16/2021 Christopher Aker
Sr. VP & General Counsel
828   Disposition at $1.72 per share. 1,424
12/04/2020 NEA Management Co. LLC
4,398,602   Acquisition at $0.62 per share. 2,727,133
12/04/2020 NEA Management Co. LLC
4,398,602   Acquisition at $0.62 per share. 2,727,133
12/04/2020 NEA Management Co. LLC
4,398,602   Acquisition at $0.62 per share. 2,727,133
12/04/2020 NEA Management Co. LLC
4,398,602   Acquisition at $0.62 per share. 2,727,133
12/04/2020 NEA Management Co. LLC
4,398,602   Acquisition at $0.62 per share. 2,727,133
12/04/2020 NEA Management Co. LLC
4,398,602   Acquisition at $0.62 per share. 2,727,133
12/04/2020 NEA Management Co. LLC
4,398,602   Acquisition at $0.62 per share. 2,727,133
12/04/2020 NEA Management Co. LLC
4,398,602   Acquisition at $0.62 per share. 2,727,133
12/04/2020 NEA Management Co. LLC
4,398,602   Acquisition at $0.62 per share. 2,727,133
12/04/2020 NEA Management Co. LLC
4,398,602   Acquisition at $0.62 per share. 2,727,133
12/04/2020 Stelios Papadopoulos
Director
793,528   Award at $0.63 per share. 499,922
12/04/2020 Stelios Papadopoulos
Director
793,528   Award at $0.63 per share. 499,922
12/04/2020 Joseph P. Hagan
President and CEO; Director
39,680   Award at $0.63 per share. 24,998
11/16/2020 Joseph P. Hagan
President and CEO; Director
6,094   Disposition at $0.52 per share. 3,168
11/16/2020 Christopher Aker
Sr. VP & General Counsel
876   Disposition at $0.52 per share. 455
08/14/2020 Joseph P. Hagan
President and CEO; Director
4,245   Disposition at $0.6 per share. 2,547
08/14/2020 Christopher Aker
Sr. VP & General Counsel
872   Disposition at $0.6 per share. 523
/news/latest/company/us/rgls

MarketWatch News on RGLS

  1. How Biotech Is Targeting RNA to Cure Diseases

    7:01 a.m. Sept. 3, 2019

    - Barron's Online

  2. Regulus Therapeutics downgraded to market perform from outperform at Leerink

    9:01 a.m. July 10, 2018

    - Tomi Kilgore

  3. Regulus Therapeutics stock price target cut to 35 cents from $2.00 at Leerink

    9:01 a.m. July 10, 2018

    - Tomi Kilgore

  4. Regulus Therapeutics stock price target cut to $6 from $8 at Wedbush Securities

    9:13 a.m. March 6, 2017

    - Tomi Kilgore

  5. Baby Boomers Pitch In

    3:24 a.m. Dec. 3, 2016

    - Barron's Online

  6. Regulus Therapeutics stock price target cut to $15 from $35 at Wedbush Securities

    6:22 a.m. June 28, 2016

    - Tomi Kilgore

  7. Regulus Therapeutics' stock resumes trade; plunges 56% in after-hours trade

    3:41 p.m. June 27, 2016

    - Tomi Kilgore

  8. Regulus Therapeutics' stock halted; FDA places hepatitis treatment on clinical hold

    3:22 p.m. June 27, 2016

    - Tomi Kilgore

  9. Regulus Therapeutics' stock soars 39% premarket after upbeat results from Hep-C treatment study

    7:44 a.m. Feb. 17, 2016

    - Tomi Kilgore

  10. Russell 2000 approaches the 200-day average

    11:35 a.m. Nov. 30, 2015

    - Michael Ashbaugh

  11. Hopes for single-dose Hepatitis C drug fade

    3:30 p.m. Feb. 9, 2015

    - Russ Britt

  12. 6 stocks to watch

    3:28 p.m. Dec. 10, 2014

    - The Trading Deck

  13. 6 stocks to watch

    3:05 p.m. Nov. 5, 2014

    - The Trading Deck

  14. Loading more headlines...
/news/nonmarketwatch/company/us/rgls

Other News on RGLS

  1. 10-Q: REGULUS THERAPEUTICS INC.

    6:02 a.m. Nov. 14, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  2. Notable earnings after Thursday's close

    5:35 p.m. Nov. 9, 2022

    - Seeking Alpha

  3. Regulus (RGLS) Up on Top-Line Data from Kidney Disease Study

    10:58 a.m. Sept. 13, 2022

    - Zacks.com

  4. ANVS, ARQQ and ALLG among mid-day movers

    12:04 p.m. Sept. 12, 2022

    - Seeking Alpha

  5. ASTS, ONTX and BITF among pre market gainers

    7:40 a.m. Sept. 12, 2022

    - Seeking Alpha

  6. 10-Q: REGULUS THERAPEUTICS INC.

    4:01 p.m. Aug. 11, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  7. Notable earnings after Thursday's close

    4:35 p.m. Aug. 10, 2022

    - Seeking Alpha

  8. 10-Q: REGULUS THERAPEUTICS INC.

    5:09 a.m. May 13, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  9. Notable earnings after Thursday's close

    4:35 p.m. May 11, 2022

    - Seeking Alpha

  10. Regulus spikes as FDA clears trial for kidney disease candidate

    10:43 a.m. May 11, 2022

    - Seeking Alpha

  11. 10-K: REGULUS THERAPEUTICS INC.

    6:05 a.m. March 11, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  12. Notable earnings after Thursday's close

    5:35 p.m. March 9, 2022

    - Seeking Alpha

  13. Biotech 101 Lecture 3: Looking At Major Biotech Catalysts

    3:23 p.m. March 8, 2022

    - Seeking Alpha

  14. Loading more headlines...

At a Glance

Regulus Therapeutics, Inc.

4224 Campus Point Court

Suite 210

San Diego, California 92121

Phone

1 8582026300

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

Revenue

N/A

Net Income

$-27.81M

Employees

26.00

/news/pressrelease/company/us/rgls

Press Releases on RGLS

  1. Hot Penny Stocks to Know About Right Now? 3 to Watch

    5:00 a.m. Sept. 13, 2022

    - Penny Stocks

  2. Regulus Therapeutics to Participate in Upcoming Investor Conferences

    3:05 p.m. Sept. 2, 2022

    - PR Newswire - PRF

  3. Regulus Appoints Amin Kamel, Ph.D., as Vice President, DMPK

    7:00 a.m. June 2, 2022

    - PR Newswire - PRF

  4. Top Penny Stocks to Buy Now? 3 to Watch in June 2022

    4:04 p.m. May 27, 2022

    - Penny Stocks

  5. Check These 3 Penny Stocks Out For Your Watchlist

    6:35 p.m. May 23, 2022

    - Penny Stocks

  6. Loading more headlines...
Link to MarketWatch's Slice.